NVIV Key Statistics, Chart & Performance
The current stock price of NVIV is 0.3207 USD. In the past month the price decreased by -58.69%. In the past year, price decreased by -84.43%.
NVIV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.02 | 217.08B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.11 | 204.83B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.56 | 142.40B | ||
| SYK | STRYKER CORP | 26.9 | 135.46B | ||
| BDX | BECTON DICKINSON AND CO | 13.62 | 56.04B | ||
| IDXX | IDEXX LABORATORIES INC | 54.6 | 54.98B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.79 | 50.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.22 | 38.09B | ||
| RMD | RESMED INC | 24.72 | 35.73B | ||
| DXCM | DEXCOM INC | 36.33 | 26.35B | ||
| PODD | INSULET CORP | 63.16 | 20.31B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.22 | 17.99B |
Related stock screener links
About NVIV
Company Profile
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
Company Info
INVIVO THERAPEUTICS HOLDINGS
Building 1400 East 4Th Floor, One Kendall Square
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Toselli
Employees: 6
Phone: 16178635524
INVIVO THERAPEUTICS HOLDINGS / NVIV FAQ
What does NVIV do?
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
What is the stock price of INVIVO THERAPEUTICS HOLDINGS today?
The current stock price of NVIV is 0.3207 USD. The price decreased by -34.28% in the last trading session.
Does NVIV stock pay dividends?
NVIV does not pay a dividend.
What is the ChartMill technical and fundamental rating of NVIV stock?
NVIV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for INVIVO THERAPEUTICS HOLDINGS?
INVIVO THERAPEUTICS HOLDINGS (NVIV) has a market capitalization of 997.38K USD. This makes NVIV a Nano Cap stock.
Who owns INVIVO THERAPEUTICS HOLDINGS?
You can find the ownership structure of INVIVO THERAPEUTICS HOLDINGS (NVIV) on the Ownership tab.
NVIV Technical Analysis
NVIV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVIV. NVIV has a great financial health rating, but its profitability evaluates not so good.
NVIV Financial Highlights
Over the last trailing twelve months NVIV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 56.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.39% | ||
| ROE | -104.6% | ||
| Debt/Equity | 0 |